1 results match your criteria: "Duke Comprehensive Cancer Center and the Duke Prostate Center[Affiliation]"
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Eur J Cancer
February 2010
Division of Medical Oncology, Department of Medicine, DUMC, Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, NC 27715, USA.
Aims Of The Study: There are no known predictive factors of response in men receiving chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). We investigated pre-treatment factors that predicted a 30% PSA decline (30% PSAD) within 3 months of starting chemotherapy, and assessed performance of a risk group classification in predicting PSA declines and overall survival (OS) in men with mCRPC.
Methods: In TAX327, 1006 men with mCRPC were randomized to receive docetaxel (D) in two schedules, or mitoxantrone (M), each with prednisone: 989 provided data on PSA decline within 3 months.